Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences

•No satisfactory treatment are current available for malignant mesothelioma patients.•Several research lines are being pursued, among them, immunotherapy seems the most one promising approach in mesothelioma.•The potential therapeutic role of targeting immune checkpoints used alone or in combination...

Full description

Saved in:
Bibliographic Details
Published in:Cytokine & growth factor reviews 2017-08, Vol.36, p.25-31
Main Authors: Calabrò, Luana, Ceresoli, Giovanni Luca, D’Incecco, Armida, Scherpereel, Arnaud, Aerts, Joachim, Maio, Michele
Format: Article
Language:English
Subjects:
CTLA-4
Immune-checkpoint
Immunotherapy
Mesothelioma
PD-1
PD-L1
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•No satisfactory treatment are current available for malignant mesothelioma patients.•Several research lines are being pursued, among them, immunotherapy seems the most one promising approach in mesothelioma.•The potential therapeutic role of targeting immune checkpoints used alone or in combination for mesothelioma is discussed. Treatment with immune-checkpoint blocking monoclonal antibody (mAb) is demonstrating a significant efficacy in different tumor types. Here, we discuss the impact of this promising approach in malignant mesothelioma (MM), a still dreadful disease in which medical treatment has been set on platinum based chemotherapy for decades with unsatisfactory results.
ISSN:1359-6101
DOI:10.1016/j.cytogfr.2017.07.003